Search results
Results from the WOW.Com Content Network
Dulaglutide, sold under the brand name Trulicity among others, [8] is a medication used for the treatment of type 2 diabetes in combination with diet and exercise. [9] [10] It is also approved in the United States for the reduction of major adverse cardiovascular events in adults with type 2 diabetes who have established cardiovascular disease or multiple cardiovascular risk factors.
The drugs were approved as additions to diet and exercise to improve blood sugar control in children aged 10 years and above with type 2 diabetes, the most common form of the disease. The ...
The same review did not find any differences in effects of using these insulin analogues between adults and children. [6] Most oral anti-diabetic agents are contraindicated in pregnancy, in which case insulin is preferred. [7] Insulin is not administered by other routes, although this has been studied.
Victoza is FDA-approved to treat type 2 diabetes but is also sometimes prescribed off-label for weight loss. Saxenda is FDA-approved for weight management in people with obesity. 3.
A large study of more than 2 million people evaluated GLP-1 agonists' benefits and risks. The study showed that GLP-1 agonists reduced risk of substance use and psychotic disorders, seizures, neurocognitive disorders (including Alzheimer’s disease and dementia), coagulation disorders, cardiometabolic disorders, infectious illnesses, and several respiratory conditions. [5]
The comments come after the FDA's staff on Wednesday flagged the risk of low blood sugar in type 1 diabetes patients, who are more insulin-dependent, and the lack of clinical data to support Novo ...
Alogliptin (FDA approved 2013 as Nesina/ Vipidia, marketed by Takeda Pharmaceutical Company) Trelagliptin (approved for use in Japan as Zafatek/ Wedica in 2015) Omarigliptin (MK-3102) (approved as Marizev in Japan in 2015, [ 12 ] developed by Merck & Co. ; research showed that omarigliptin can be used as once-weekly treatment and generally well ...
In combination with palbociclib and fulvestrant for the treatment of adults with endocrine-resistant, PIK3CA-mutated, hormone receptor (HR)-positive, human epidermal growth-factor receptor 2 (HER2)-negative, locally advanced or metastatic breast cancer, as detected by an FDA-approved test, following recurrence on or after completing adjuvant ...